Rationale and Future of Ide-Cel: Larry D. Anderson, Jr, MD, PhD
The hematologist/oncologist at the Harold C. Simmons Comprehensive Cancer Center discussed the rationale behind using CAR T-cell therapy in relapsed/refractory multiple myeloma and data from the KarMMa trial.
Using Cell Therapies for Cancer and Beyond
Jennifer Buell, PhD, president and chief operating officer of Agenus, discussed cell therapy for multiple myeloma and COVID-19 respiratory distress.
CARTITUDE Trials in Multiple Myeloma
Experts discussed safety and efficacy data of cilta-cel for R/R MM from the CARTITUDE-1 and CARTITUDE-2 studies.
Addressing Unmet Needs With Gene Therapy
Eric Crombez, PhD, senior vice president and chief medical officer of Ultragenyx Gene Therapy, discussed indications the company is targeting.
Gene Therapy for Retinal and Neurological Diseases
Magali Taiel, MD, chief medical officer, GenSight Biologics, discussed future research the company plans to pursue.
Investigational Agents in Relapsed/Refractory Myeloma
Experts discuss emerging agents in the pipeline for the treatment of RRMM; including BCMA-targeted bispecific antibodies.
Allogeneic Stem Cell Transplant for Acute Myeloid Leukemia
The hematologist from UC Health discussed the role of allogeneic stem cell transplant at first remission based on risk stratification.
Future CAR T Therapy Research in Multiple Myeloma: Krina K. Patel, MD, MSc
The associate professor from The University of Texas MD Anderson Cancer Center discussed future research with CAR T therapy in multiple myeloma.
Emerging Data in Diffuse Large B-Cell Lymphoma
Experts discussed data from trials in lymphoma presented at ASCO 2021.
CAR T-Cell Therapy's Potential in Non-Hodgkin Lymphoma: Julie Vose, MD
The chief of Oncology and Hematology at University of Nebraska Medical Center, discussed the potential utility of CAR T-cell therapy across the non-Hodgkin lymphoma (NHL) paradigm.
Using A Modular Approach to Develop Oncolytic Cell Therapies
The chief executive and chief medical officers of Celyad Oncology discussed their platform and positive data presented at EHA 2021.
The Future of Gene Therapies in Inherited Retinal Diseases
Mariya Moosajee, MBBS, BSc, PhD, FRCOphth, discussed the next generation of gene therapy for inherited retinal diseases.
Investigating the Role of HTRA1 in Developing AMD: Brandi L. Williams, PhD
The research director at the Moran Eye Center discussed the genetics of developing age-related macular degeneration.
Treatment Options After CAR T Therapy for Large B-Cell Lymphoma
The professor of medicine from Duke University School of Medicine discussed treatment approaches for after relapse on CAR T cell therapy or for patients who are ineligible for CAR T therapy.
Tackling Dravet Syndrome With Gene Therapy
Salvador Rico, MD, PhD, chief medical officer, Encoded Therapeutics, discussed the different initiatives the company is conducting in Dravet syndrome.
Addressing Unmet Needs in Mantle Cell Lymphoma With CAR T Therapy: Anita Kumar, MD
The medical oncologist from Memorial Sloan Kettering Cancer Center discussed efforts made to address areas of unmet need in mantle cell lymphoma.
Treating Endothelial Disease With One Cornea Donor
Edward Holland, MD, chief medical advisor, discussed an injectable technique where one cornea donor could potentially supply hundreds of patients with treatment for endothelial disease.
Using CAR T Therapy in R/R Multiple Myeloma
Nina Shah, MD, and other experts discuss the role of CAR T-cell therapy in relapsed/refractory multiple myeloma.
Selecting AAV Manufacturing Platforms
The chief scientific officer and chief medical officer of Ultragenyx Gene Therapy discussed the company’s future research in gene therapies.
Developing Oncolytic Cell Therapies With VISION
Jennifer Buell, PhD, president and chief operating officer of Agenus, discussed the VISION platform the company uses to develop therapies.
Future Research in Gene and Cell Therapy Conditioning
Kevin Heller, MD, executive vice president of research, Jasper Therapeutics, discussed future research with JSP191.
Immunotherapy and CAR T-Cell Therapy: Stephen M. Ansell, MD, PhD
The chair of the Lymphoma Group at Mayo Clinic discussed incorporating immunotherapies beyond CAR T-cell therapy in non-Hodgkin lymphoma.
Challenges With CAR T Therapy in Follicular Lymphoma: Sattva S. Neelapu, MD
The professor from the University of Texas Anderson Cancer Center discussed challenges surrounding CAR T-cell therapy for the treatment of follicular lymphoma and other lymphomas.
Future Research With CAR T in Lymphoma: Julie Vose, MD
The professor and chief, of oncology and hematology at University of Nebraska Medical Center discussed research with CAR T therapy in lymphoma.
CAR T Therapy in Non-Hodgkin Lymphoma: Kelly Garvin, BSN, RN
The lymphoma specialist from Moffitt Cancer Center discussed the advantages of CAR T-cell therapy in non-Hodgkin lymphoma.
Targeting LHON and Retinitis Pigmentosa With Gene Therapy
Magali Taiel, MD, chief medical officer, GenSight Biologics, discussed the company’s work in ophthalmic diseases.
Allogeneic vs Autologous CAR T-Cell Therapies
The chief executive and chief medical officer of Celyad Oncology discussed the advantages of allogeneic CAR T therapies over autologous ones.
Understanding the Genetics of Age-Related Macular Degeneration: Gregory S. Hageman, PhD
The executive director of the Steele Center for Translational Medicine at the Moran Eye Center discussed the research his team has been conducting in AMD.
Weighing Benefits and Risks of Cell Therapy in Multiple Myeloma: Suzanne Lentzsch, MD
The professor of clinical medicine, director, Multiple Myeloma and Amyloidosis Program, New York-Presbyterian Hospital, discussed utility of cellular therapies in multiple myeloma.
Selecting CAR T-Cell Therapies for R/R DLBCL
Experts discuss the use and selection of CAR T therapies in relapsed/refractory diffuse large B-cell lymphoma.
